UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

The New England journal of medicine, 2018-08, Vol.379 (7), p.645-654

2018

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

Antimicrobial Agents and Chemotherapy, 2009-02, Vol.53 (2), p.450-457

2009

Volltextzugriff (PDF)

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

Journal of Virology, 2011-04, Vol.85 (8), p.3872-3880

2011

Volltextzugriff (PDF)

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment

Antiviral research, 2011-12, Vol.92 (3), p.484-487

2011

Volltextzugriff (PDF)

Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study

Journal of acquired immune deficiency syndromes (1999), 2021-04, Vol.86 (4), p.482-489

2021

Volltextzugriff (PDF)

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

AIDS (London), 2022-07, Vol.36 (8), p.1055-1060

2022

Volltextzugriff (PDF)

1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311)

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S532-S532

2020

Volltextzugriff (PDF)

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S542-S543

2020

Volltextzugriff (PDF)

544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S202-S202

2018

Volltextzugriff (PDF)

Development of Oseltamivir Phosphonate Congeners as Anti-influenza Agents

Journal of medicinal chemistry, 2012-10, Vol.55 (20), p.8657-8670

2012

Volltextzugriff (PDF)

Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S38-S39

2017

Volltextzugriff (PDF)

A Genetic Approach to Promoter Recognition during Trans Induction of Viral Gene Expression

Science (American Association for the Advancement of Science), 1986-10, Vol.234 (4772), p.53-59

1986

Volltextzugriff (PDF)

Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

The role of viruses in human cancer development and antiviral approaches for intervention

Current opinion in investigational drugs (London, England : 2000), 2002-11, Vol.3 (11), p.1574

2002

Volltextzugriff (PDF)

Identification of a Novel Peptide Substrate of HSV-1 Protease Using Substrate Phage Display

Virology (New York, N.Y.), 1997-09, Vol.236 (2), p.338-347

1997

Volltextzugriff (PDF)

Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts (∗)

The Journal of biological chemistry, 1995-12, Vol.270 (50), p.30168-30172

1995

Volltextzugriff (PDF)

The Effect of Internal Autocleavage on Kinetic Properties of the Human Cytomegalovirus Protease Catalytic Domain (∗)

The Journal of biological chemistry, 1995-03, Vol.270 (9), p.4753-4758

1995

Volltextzugriff (PDF)

Herpes simplex virus VP16 rescues viral mRNA from destruction by the virion host shutoff function

The EMBO journal, 1996-05, Vol.15 (10), p.2575-2581

1996

Volltextzugriff (PDF)

Deletion of the VP16 open reading frame of herpes simplex virus type 1

Journal of Virology, 1992-01, Vol.66 (1), p.258-269

1992

Volltextzugriff (PDF)

Identification of the serine residue at the active site of the herpes simplex virus type 1 protease

The Journal of biological chemistry, 1994-04, Vol.269 (17), p.12672-12676

1994

Volltextzugriff (PDF)

Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus

Journal of Virology, 1994-09, Vol.68 (9), p.5384-5394

1994

Volltextzugriff (PDF)

In vitro Proteolytic Activity and Active‐Site Identification of the Human Cytomegalovirus Protease

European journal of biochemistry, 1994-12, Vol.226 (2), p.361-367

1994

Volltextzugriff (PDF)

The human cytomegalovirus UL98 gene encodes the conserved herpesvirus alkaline nuclease

Journal of general virology, 1997-11, Vol.78 (11), p.2953-2961

1997

Volltextzugriff (PDF)

The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids

Journal of Virology, 1995-07, Vol.69 (7), p.4347-4356

1995

Volltextzugriff (PDF)

Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles

Journal of Virology, 1993-10, Vol.67 (10), p.5813-5822

1993

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(72)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment

Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311)

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants

544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial

Development of Oseltamivir Phosphonate Congeners as Anti-influenza Agents

Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

A Genetic Approach to Promoter Recognition during Trans Induction of Viral Gene Expression

Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection

The role of viruses in human cancer development and antiviral approaches for intervention

Identification of a Novel Peptide Substrate of HSV-1 Protease Using Substrate Phage Display

Stimulation of the Herpes Simplex Virus Type I Protease by Antichaeotrophic Salts (∗)

The Effect of Internal Autocleavage on Kinetic Properties of the Human Cytomegalovirus Protease Catalytic Domain (∗)

Herpes simplex virus VP16 rescues viral mRNA from destruction by the virion host shutoff function

Deletion of the VP16 open reading frame of herpes simplex virus type 1

Identification of the serine residue at the active site of the herpes simplex virus type 1 protease

Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus

In vitro Proteolytic Activity and Active‐Site Identification of the Human Cytomegalovirus Protease

The human cytomegalovirus UL98 gene encodes the conserved herpesvirus alkaline nuclease

The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids

Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles

Suchergebnisse filtern